09:35 AM EDT, 03/12/2024 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) said Tuesday that it has signed a clinical trial collaboration and supply deal with Merck ( MRK ) to evaluate IDE161 in combination with Merck's ( MRK ) Keytruda to treat patients with endometrial cancer in a phase 1 clinical trial.

Financial terms were not disclosed.

Under the agreement, Merck ( MRK ) will provide Keytruda to IDEAYA, which will be the sponsor of the trial. Each company will retain all commercial rights to their respective compounds, including as monotherapy or as combination therapies, IDEAYA said.

Price: 43.39, Change: -0.19, Percent Change: -0.44